Lilly depression drug fails to meet goals in studies
Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.
Health Care Businesses
Articles
Lilly invests in NY life sciences venture capital initiative
Indianapolis-based Eli Lilly and Co. has joined two other companies to contribute $40 million to an early-stage life sciences venture capital initiative in New York City.
Lilly called likely suitor for Novartis veterinary unit
Novartis AG’s animal-health business is drawing interest from drugmakers including Indianapolis-based Eli Lilly and Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of the matter said.
Lilly to spend another $700M in growing market for diabetes products
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
Testosterone drugs raise heart risk, study finds
Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
Lawmakers considering more changes to patent laws
U.S. lawmakers, influenced by companies including Indianapolis-based Eli Lilly and Co., Cisco Systems Inc. and Qualcomm Inc., are considering the second set of patent-law changes in three years as the courts try to race ahead of Congress.
Bribery scandals sap Lilly’s China growth
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
Franciscan hospitals to eliminate 925 full-time positions
The Indiana-based system that operates three hospitals in the Indianapolis area said it is trying to cut its expenses by as much as $500 million, or 20 percent.
State medical institute snares $30M grant from feds
A consortium of Indiana University, Purdue University and University of Notre Dame can operate for another five years with the grant funds.
Lilly stock shrugs off analyst downgrade
The drugmaker has become too reliant on its remaining pipeline of drugs under development for growth as it deals with patent expirations to big sellers and drug-development setbacks, a Jefferies analyst wrote.
Clinic operator Novia to be purchased by Wisconsin firm
Indianapolis-based Novia CareClinics LLC was a pioneer in operating primary care clinics for employers. In 2012, Novia had 175 employees and more than $15 million in revenue.
Lilly volunteer service day blooms into citywide effort
More than 60 companies plan to participate in the three-day Indy Do Day volunteer marathon, which kicks off Thursday in conjunction with Eli Lilly and Co.’s Global Day of Service.
Financial pressures stretching Lilly
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Lilly, other drugmakers itching to find new psoriasis treatment
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Lilly to buy back $5B as sales goal harder to reach
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
IU Health now says 935 jobs affected by reductions
Indiana University Health now says it will cut more than 900 jobs in a reorganization. That's at least 100 more than announced nearly three weeks ago.
Lilly shares dip after cancer treatment misses goal
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
Lilly bets quality over quantity will pay off in diabetes battle
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Alzheimer’s targeted in $45M government study grant
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
Analyst foresees managed care growth in 2014
Major health insurers like WellPoint Inc. are in line for another year of growth, as the health care overhaul implements key elements in its push to cover millions of uninsured people.